---
title: "Cellectis H1 FY26 net loss narrows 5.49% to USD 39.58 million; revenue drops 52.19% to USD 14.45 million"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295140687.md"
description: "Cellectis reported a narrowed H1 FY26 net loss of USD 39.58 million, down 5.49%, while revenue dropped 52.19% to USD 14.45 million due to reduced AstraZeneca collaboration activity. Operating losses widened to USD 48.69 million as R&D costs rose. However, net financial results swung to a USD 9.18 million gain from fair-value adjustments. The company holds USD 169 million in cash, guiding its runway through Q4 2027."
datetime: "2026-08-06T20:33:38.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295140687.md)
  - [en](https://longbridge.com/en/news/295140687.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295140687.md)
generator: "portal-rs"
---

# Cellectis H1 FY26 net loss narrows 5.49% to USD 39.58 million; revenue drops 52.19% to USD 14.45 million

-   Cellectis posted a net loss attributable to shareholders of USD 39.6 million, or USD 0.39 a share, for the half-year ended June 30. \* Revenue and other income fell 52.2% to USD 14.45 million, reflecting lower activity under its AstraZeneca research collaboration plans. \* Operating loss widened to USD 48.69 million as R&D costs rose to USD 52.17 million on higher staffing and clinical development spending. \* Net financial result swung to a gain of USD 9.18 million, driven by fair-value gains on EIB warrants and lower FX losses. \* Cash, cash equivalents and term deposits totaled USD 169 million at June 30; cash runway guided through Q4 2027, with BALLI-01 interim Phase 2 data due Q4 2026. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cellectis SA published the original content used to generate this news brief on August 06, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here

### Related Stocks

- [CLLS.US](https://longbridge.com/en/quote/CLLS.US.md)
- [AZN.US](https://longbridge.com/en/quote/AZN.US.md)
- [AZN.UK](https://longbridge.com/en/quote/AZN.UK.md)

## Related News & Research

- [Cellectis expects interim readout in Q4 2026 from pivotal BALLI-01 trial of lasme-cel in relapsed/refractory B-cell ALL](https://longbridge.com/en/news/295149883.md)
- [Cellectis publishes corporate presentation on allogeneic CAR-T pipeline, TALEN gene-editing platform](https://longbridge.com/en/news/295217037.md)
- [This is the No. 1 CD of August 2026](https://longbridge.com/en/news/296082294.md)
- [Kreditbanken posts 2026 half-year report release](https://longbridge.com/en/news/296349936.md)
- [Rockwool announces availability of 2026 half-year report](https://longbridge.com/en/news/296326112.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**